Beacon Biosignals has secured the US Food and Drug Administration’s (FDA) 510(k) clearance for SleepStageML, a machine learning software designed to enhance sleep analysis.

This development expands the company’s analytical capabilities, extending from at-home sleep monitoring to include in-lab polysomnography, a traditional method for diagnosing sleep disorders.

SleepStageML is designed to help improve the diagnosis and evaluation of sleep and sleep-related disorders.

It utilises deep-learning to automatically stage sleep from electroencephalogram (EEG) signals in clinical polysomnography (PSG) recordings.

The software’s deep-learning model was trained on a substantial dataset comprising hundreds of thousands of hours of PSG recordings from a diverse patient population.

Clinical validation has shown that SleepStageML’s performance is on par with or surpasses that of individual human experts.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Some of the benefits of SleepStageML include reducing variability in human scoring, automating the manual sleep staging process, and supporting quicker PSG analysis turnaround times.

A noteworthy aspect of SleepStageML’s FDA clearance is the inclusion of a Predetermined Change Control Plan (PCCP).

This approach allows the company to continuously enhance the machine learning algorithm while maintaining compliance with the original 510(k) clearance.

Beacon Biosignals analytics and machine learning vice-president Alexander Chan said: “SleepStageML’s approved PCCP is a game-changing development for the sleep field.

“With this regulatory pathway, we can provide even more accurate and robust sleep staging capabilities over time. This ability to iteratively enhance SleepStageML will be invaluable for generating insights to accelerate sleep therapy research and development.”

Last year, Beacon Biosignals obtained FDA 510(k) clearance for its AI-assisted sleep monitoring device, Dreem 3S.

Beacon Biosignals CEO Jacob Donoghue said: “With FDA clearances for both SleepStageML and Dreem 3S headband, Beacon now provides an unparalleled capability to measure sleep physiology whether studies are conducted in-home or in-clinic.

“Beacon’s powerful analytics platform allows for a rich analysis of clinical datasets across multiple environments to spur innovation in therapies for sleep disorders as well as neurological and psychiatric conditions with sleep comorbidities.”